Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8304422
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: November 6, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • Patent number: 8299087
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: October 30, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • Publication number: 20120264740
    Abstract: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Application
    Filed: March 19, 2012
    Publication date: October 18, 2012
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Jing Zhang, Rajinder Singh, Sacha Holland, Jiaxin Yu, Thilo J. Heckrodt, Pingyu Ding, Joane Litvak
  • Publication number: 20120259779
    Abstract: Embodiments of the present invention provide a method for a server performing a wireless payment transaction, comprising: providing a server web page or native application including options for a user selecting a role as payer or payee; requesting information from the payee including a transaction ID provided by the server; requesting information from the payer including the transaction ID; initiating an authorization of the transaction on a credit or debit account of the payer; initiating a transaction to credit the payee's account; and completing the transaction with the payer by initiating the offline clearing of the transaction.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 11, 2012
    Applicant: OnDot Systems, Inc.
    Inventors: Vaduvur Bharghavan, Jari Malinen, Rajinder Singh, Jason Fieldman, Rachna Ahlawat, Kannan Konath, Sandeep Gilotra
  • Publication number: 20120253039
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 4, 2012
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • Patent number: 8278299
    Abstract: The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: October 2, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Andy Atuegbu, John Ramphal, Hui Li, Marina Gelman, Jeffrey Clough, Carlos Valdez, Somasekhar Bhamidipati, Sambaiah Thota, Darren McMurtrie
  • Publication number: 20120245127
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh
  • Patent number: 8268851
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 18, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Hui Li, Rajinder Singh, Vanessa Taylor, Jeffrey Clough, Darren McMurtrie
  • Patent number: 8269023
    Abstract: An improved process for synthesis of duloxetine hydrochloride (1) having chiral purity greater than 99.9% that is characterized by the following: (i) preparation of racemic condensed compound (RS)—N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine (4) by reaction of racemic hydroxy compound (2) with 1-fluoronaphthalene (3) in presence of a base such as sodamide, potassium amide or potassium bis(trimethylsilyl)amide (KHDMS) in polar aprotic solvent, (ii) optical resolution of racemic condensed compound (5a+5b) with di-benzoyl-L-tartaric acid (7, DBTA, R=H) or di-para-anisoyl-L-tartaric acid (7, DATA, R=OCH3) to obtain crude (S)—N.N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine dibenzoyl tartarate salt (8a) or (S)—N.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: September 18, 2012
    Assignee: Lupin Ltd.
    Inventors: Rajinder Singh Siyan, Sunil Kumar Vinubhai Gohel, Girij Pal Singh
  • Publication number: 20120232036
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 13, 2012
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
  • Publication number: 20120232160
    Abstract: The present invention provides a novel insecticide formulation that not only demonstrates strong insecticidal and residual activity against a variety of insects, but also exhibits low mammalian toxicity.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 13, 2012
    Inventors: Phillip Edward Kaufman, Rajinder Singh Mann, Jerry Frank Butler
  • Publication number: 20120230984
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Application
    Filed: March 13, 2012
    Publication date: September 13, 2012
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • Publication number: 20120213795
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.
    Type: Application
    Filed: May 3, 2012
    Publication date: August 23, 2012
    Inventors: Hui Li, Ankush Argade, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Kin Tso, Somasekhar Bhamidipati
  • Publication number: 20120208785
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: March 12, 2012
    Publication date: August 16, 2012
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
  • Patent number: 8227455
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: July 24, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh
  • Patent number: 8211888
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: July 3, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
  • Patent number: 8211889
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: July 3, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Thomas Sun, Valentino J. Stella
  • Publication number: 20120142915
    Abstract: This disclosure concerns a protected cyclopropylboronic acid comprising a substituted cyclopropyl group and a boronic ester group having a protecting group. The protecting group is an N-methyliminodiacetic acid (MIDA) group or MIDA-based group.
    Type: Application
    Filed: December 1, 2011
    Publication date: June 7, 2012
    Inventors: Matthew Duncton, Rajinder Singh
  • Patent number: 8193197
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: June 5, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Kin Tso, Somasekhar Bhamidipati
  • Patent number: 8188276
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 29, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G Payan, Susan Molineaux, Sasha J Holland, Jeffrey Wayne Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B Rossi